prof. Bart De Spiegeleer (PhD)

CRIG group leader
Bart De Spiegeleer


Principal investigator - Head of DruQuaR laboratory
Full professor (Faculty of Pharmaceutical Sciences, UGent)

 

Research focus

    Our group focuses on:

    1)  Quality and analytics of (anticancer) medicines (small molecules and biologics) for discovery, preclinical investigations, clinical trials and post-approvals (GMP-laboratory).
    2)  Regulatory affairs, from discovery to market access.
    3)  Peptides as bioactive molecules (biomarkers, medicines): (bio)analytics, target interaction, pharmacodynamics and pharmacokinetics (receptor, cell, tissue/organ, rodent). Peptides are also involved in cancer, and as such, they can be used as biomarkers but also as theranostics. Two examples from our group highlight the role of peptides in cancer: 

    1. quorum sensing peptides, produced by micro-organisms including our microbiome, have been demonstrated i.a. to promote metastasis. Hence, this group of bacterial molecules is also an explanatory factor in the host-microbiome interaction (e.g .CRC, breast and oral cancers)
    2. Cryptic peptides, derived from proteins (eg human growth hormone), can be used as novel lead molecules to target cancer cells (e.g. melanoma).

    Next to our interest in peptides, we are experienced in establishing quality specifications and analytics of investigational and marketed medicines used in oncology, e.g. asparaginase.

    Of note, our team is also involved in the Ghent University Expertise Centre MSsmall (mass spectrometry analysis of small organic molecules), and is a GMP (EU recognized) laboratory for quality evaluation of medicines.
    Finally, we have experience in ADME in rodents (incl. BBB study) and transdermal/mucosal diffusion experiments (Franz cells using human skin and porcine oral mucosa).
     

    Biography

    • 1989: PhD pharmaceutical Sciences
    • 1989-1994: Qualified person, regulatory affairs and technical director in pharmaceutical industry
    • 1994-2008: founder and CEO several small enterprises in pharmaceutical and related fields
    • 2004-2008: part-time guest lecturer UGhent
    • 2008-now: professor UGhent

       

    Research team

    • Prof. Bart De Spiegeleer – principal investigator, full professor
    • Dr. Evelien Wynendaele – post-doctoral fellow
    • Nathan Debunne – doctoral fellow
    • Liesa Tack – doctoral fellow
    • Han Yao – doctoral fellow
    • dr. Anton De Spiegeleer (MD) - doctoral fellow
       

    Key publications

    • Crosstalk between the microbiome and cancer cells by quorum sensing peptides - E Wynendaele, F Verbeke, M D’hondt, A Hendrix, C Van De Wiele, ... - Peptides (2015) 64, 40-48
    • The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro - B De Spiegeleer, F Verbeke, M D’Hondt, A Hendrix, C Van De Wiele, ... - PLoS One (2015) 10 (3)
    • In Vitro Functional Quality Characterization of NOTA-Modified Somatropins - Bracke, Nathalie; Yao, Han; Wynendaele, Evelien; et al. - Analytical chemistry (2017)  Volume:  89    Issue:  5    Pages:  2764-2772  
       

    Contact & links

    • Lab address: DruQuaR, Faculty Pharmaceutical Sciences, Ottergemse steenweg 460, B-9000 Gent.
    • DruQuaR laboratory 
    • Twitter 
    • Google Scholar
    • prof. De Spiegeleer is interested to receive invitations for talks or presentations